Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Celecoxib + Nirogacestat |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Celecoxib | Celecoxib is a COX-2 inhibitor that blocks inflammatory response and has anti-angiogenic and anti-proliferative activities (PMID: 31726219), which may lead to tumor growth inhibition (PMID: 17909047, PMID: 16740761). | |||
Nirogacestat | Ogsiveo | PF-03084014|PF 03084014|PF03084014 | Gamma secretase inhibitor 13 | Ogsiveo (nirogacestat) is a small molecule that selectively binds to Gamma-secretase and inhibits its proteolytic activity on downstream targets including NOTCH receptor proteins, thus blocking NOTCH pathway activation in cancer (PMID: 28887726, PMID: 31211955). Ogsiveo (nirogacestat) is FDA-approved for use in patients with progressing desmoid tumors (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC T1556Nfs*3 | desmoid tumor | predicted - sensitive | Celecoxib + Nirogacestat | Case Reports/Case Series | Actionable | In a clinical case study, addition of Ogsiveo (nirogacestat) to Celecoxib treatment resulted in a reduction in tumor size and stable disease that was ongoing for at least 17 months in a pediatric patient with a desmoid tumor harboring APC T1556Nfs*3 (PMID: 32762028). | 32762028 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|